Activation of 4-1BBL(+) B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma

Immunotherapy has revolutionized the treatment of many tumors. However, most glioblastoma (GBM) patients have not, so far, benefited from such successes. With the goal of exploring ways to boost anti-GBM immunity, we developed a B cell–based vaccine (B(Vax)) that consists of 4-1BBL(+) B cells activa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee-Chang, Catalina, Miska, Jason, Hou, David, Rashidi, Aida, Zhang, Peng, Burga, Rachel A., Jusué-Torres, Ignacio, Xiao, Ting, Arrieta, Victor A., Zhang, Daniel Y., Lopez-Rosas, Aurora, Han, Yu, Sonabend, Adam M., Horbinski, Craig M., Stupp, Roger, Balyasnikova, Irina V., Lesniak, Maciej S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527974/
https://www.ncbi.nlm.nih.gov/pubmed/32991668
http://dx.doi.org/10.1084/jem.20200913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527974/
https://www.ncbi.nlm.nih.gov/pubmed/32991668
http://dx.doi.org/10.1084/jem.20200913

Ejemplares similares